p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0292189 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Özgün Le Roux und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, North Carolina, United States of America. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Mice engineered with a G12D versus Q61R mutation in Kras exhibited differences in tumorigenesis. Namely, the incidence or grade of oral or forestomach squamous epithelial lesions was more prevalent in the Kras G12D background while hematolymphopoietic disease was more prevalent in the Kras Q61R background. Loss of the Trp53 gene encoding the tumor suppressor p53 enhances the ability of oncogenic Kras to initiate tumorigenesis in carcinogen and genetic models of lung cancer. Conversley, an extra copy of Trp53 ( Super p53 ) was recently shown to suppress Kras-induced tumorigenesis in a genetic model of this disease. Given this, we evaluated whether an extra copy of Trp53 would alter tumorigenesis upon global activation of a modified Kras allele engineered with either a G12D or Q61R mutation. We report that an increase in p53 dosage significantly reduced the incidence or grade of oral and forestomach squamous tumors induced by either G12D and Q61R-mutant Kras. The incidence of myeloproliferative disease was also significantly reduced with increased p53 dosage in the Kras Q61R background. Both the percentage of mice with lung tumors and total number of adenomas per animal were unchanged. However, the incidence and grade of peripheral atypical alveolar hyperplasia was significantly decreased in both backgrounds with increased p53 dosage. Finally, the number of foci of bronchioloalveolar hyperplasia per animal significantly increased with increased p53 dosage in the Kras G12D background. These results suggest that an extra copy of p53 can impede oncogenic Kras driven tumorigenesis in some tissues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Cancer Biology, Duke University Medical Center, Durham, North Carolina, United States of America.
- Department of Pathology, Duke University Medical Center, Durham, North Carolina, United States of America.
ORCID-Profile: Christopher M Counter
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Le Roux, Ö., Everitt, J. I., & Counter, C. M. (2024). p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis. PLOS ONE. https://doi.org/10.1371/journal.pone.0292189
Vancouver
Le Roux Ö, Everitt JI, Counter CM. p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis. PLOS ONE. 2024. doi:10.1371/journal.pone.0292189
BibTeX
@article{LeRoux2024,
author = {Le Roux, Özgün and Everitt, Jeffery I and Counter, Christopher M},
title = {p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0292189}
}
EUVIMED